| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Veraguensin targets multiple biological pathways including oxidative stress-responsive pathways and inflammatory signaling. The compound exhibits antioxidant activity through free radical scavenging mechanisms. Its anti-inflammatory effects are mediated through inhibition of pro-inflammatory cytokine production and modulation of NF-κB signaling. The compound may also exhibit anticancer activity through induction of apoptosis and inhibition of cell proliferation.
|
|---|---|
| ln Vitro |
In vitro, veraguensin exhibits antioxidant activity through free radical scavenging. It demonstrates anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines. The compound may also show anti-cancer activity by inducing apoptosis in cancer cell lines. Its effects on cell signaling pathways have been characterized in cellular models, with modulation of inflammatory and oxidative stress pathways observed.
|
| ln Vivo |
In vivo studies on veraguensin are limited. Based on its mechanism of action, the compound may have potential in inflammatory disorders and oxidative stress-related conditions. Its antioxidant and anti-inflammatory properties suggest potential therapeutic applications. Further in vivo studies are needed to fully characterize its pharmacological effects and therapeutic potential.
|
| Enzyme Assay |
For in vitro antioxidant assays, veraguensin can be evaluated using DPPH or ABTS radical scavenging assays. The compound is incubated with radical solutions, and the decrease in absorbance is measured. Scavenging activity is calculated as a percentage. Anti-inflammatory activity can be assessed by measuring inhibition of pro-inflammatory cytokine production in stimulated cells using ELISA.
|
| Cell Assay |
For in vitro cell-based assays, veraguensin is typically tested on immune cells or cancer cell lines. Cells are treated with the compound at various concentrations (typically 1-100 μM) for 24-72 hours. Cell viability is assessed using MTT or CCK-8 assays. Cytokine production is measured by ELISA. Apoptosis is evaluated by flow cytometry. Signaling pathway modulation is assessed by Western blotting.
|
| Animal Protocol |
In vivo animal experiments for veraguensin have not been extensively reported. Based on its anti-inflammatory and antioxidant activities, potential experimental models include inflammation models in mice or rats. The compound could be administered orally or intraperitoneally, with inflammatory markers assessed as pharmacodynamic endpoints.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for veraguensin are limited. As a lignan, it is expected to have moderate oral bioavailability. Standard pharmacokinetic studies would be required to determine its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for veraguensin are limited. As a natural product isolate, it is generally considered to have low toxicity at pharmacological doses. However, comprehensive toxicological studies have not been extensively reported. The compound is classified as a research-grade reagent and is not for human use.
|
| References | |
| Additional Infomation |
Veraguensin is a lignan that functions as a metabolite. It has been reported to be found in Nectandra angustifolia, Nectandra puberula, and other organisms with relevant data.
Veraguensin is a research-use only compound and has not been approved for clinical applications. It is a lignan natural product. Its molecular weight and formula are well-characterized. It is available from various research chemical suppliers. Further research is needed to fully elucidate its pharmacological profile and therapeutic potential. |
| Molecular Formula |
C22H28O5
|
|---|---|
| Molecular Weight |
372.4547
|
| Exact Mass |
372.194
|
| CAS # |
19950-55-1
|
| PubChem CID |
443026
|
| Appearance |
White to off-white solid
|
| Density |
1.082±0.06 g/cm3
|
| Boiling Point |
479.1±45.0℃(Predicted)
|
| Melting Point |
128.0-129.2 ºC (methanol)
|
| Vapour Pressure |
7.04E-09mmHg at 25°C
|
| LogP |
4.805
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
27
|
| Complexity |
418
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O1[C@@]([H])(C2C([H])=C([H])C(=C(C=2[H])OC([H])([H])[H])OC([H])([H])[H])[C@@]([H])(C([H])([H])[H])[C@]([H])(C([H])([H])[H])[C@@]1([H])C1C([H])=C([H])C(=C(C=1[H])OC([H])([H])[H])OC([H])([H])[H]
|
| InChi Key |
JLJAVUZBHSLLJL-GKHNXXNSSA-N
|
| InChi Code |
InChI=1S/C22H28O5/c1-13-14(2)22(16-8-10-18(24-4)20(12-16)26-6)27-21(13)15-7-9-17(23-3)19(11-15)25-5/h7-14,21-22H,1-6H3/t13-,14-,21-,22+/m0/s1
|
| Chemical Name |
(2S,3S,4S,5R)-2,5-bis(3,4-dimethoxyphenyl)-3,4-dimethyloxolane
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~67.12 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 1.25 mg/mL (3.36 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.36 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6849 mL | 13.4246 mL | 26.8492 mL | |
| 5 mM | 0.5370 mL | 2.6849 mL | 5.3698 mL | |
| 10 mM | 0.2685 mL | 1.3425 mL | 2.6849 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
